Results 101 to 110 of about 46,487 (292)
Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes +6 more
wiley +1 more source
The phytocannabinoid, Δ(9) -tetrahydrocannabivarin, can act through 5-HT1 A receptors to produce antipsychotic effects [PDF]
Funded by: •GW Pharmaceuticals Acknowledgements: The authors wish to thank Mrs Lesley Stevenson for technical support and Dr John Raymond, Dr Keith Parker and Dr Ethan Russo for providing human 5-HT1A CHO cells.
Cascio, Maria Grazia +4 more
core +1 more source
Complementary and Integrative Medicine for the Treatment of Tourette's Syndrome
Abstract Background There is widespread interest in complementary and integrative medicine (CIM) among people with Tourette's syndrome (TS). Objective To perform a systematic review of evidence on the use of CIM to reduce tics and improve tic‐related quality of life.
Tamara Pringsheim +21 more
wiley +1 more source
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan +4 more
wiley +1 more source
Aims: Elevated prolactin levels due to antipsychotic drugs are prevalent in elderly patients and may cause multiple complications. Hence, the purpose of the present study is to compare the effectiveness of changing existing antipsychotic treatments with ...
Gaurav Uppal +4 more
doaj +1 more source
Predictors of switching antipsychotic medications in the treatment of schizophrenia
Background To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia.
Stauffer Virginia L +4 more
doaj +1 more source
Antipsychotic‐Induced Hyperprolactinemia [PDF]
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90238/1/phco.29.1.64 ...
Bostwick, Jolene R. +2 more
core +1 more source
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu +13 more
wiley +1 more source
Abstract Background and Objective Previous work from this dataset found 45% prescribing frequency of any medications (35.1%, 33.5%, and 56.8% at institutions 1, 2, and 3 respectively), without significant difference between in‐person and telemedicine.
Matthew Chen +7 more
wiley +1 more source
Antipsychotics induced hyperprolactinaemia and osteoporosis
Antipsychotic drugs block dopamine D2 receptors and thus remove the inhibitory influence on prolactin secretion. Hyperprolactinemia is a common side effect of treatment with antipsychotics.
Semiha Tufan Temiz, Atila Erol
doaj

